Matinas BioPharma Holdings (MTNB) Cash & Equivalents (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has reported Cash & Equivalents for 14 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 65.37% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 65.37% YoY), while the FY2025 annual figure was $4.0 million, down 45.1% from the prior year.
• Cash & Equivalents retreated to $2.4 million in Q1 2026 per MTNB's latest filing, from $4.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $19.3 million in Q1 2022 and bottomed at $1.1 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $7.2 million across 5 years, with a median of $6.5 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 81.34% — and 2025, when it surged 546.5%.
• Matinas BioPharma Holdings' Cash & Equivalents stood at $6.8 million in 2022, then fell by 29.91% to $4.8 million in 2023, then jumped by 52.16% to $7.3 million in 2024, then tumbled by 45.1% to $4.0 million in 2025, then tumbled by 40.04% to $2.4 million in 2026.
• Business Quant data shows MTNB's Cash & Equivalents at $2.4 million in Q1 2026, $4.0 million in Q4 2025, and $5.4 million in Q3 2025.